Work

A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4501

Authors: Xu Hu, Xu Shi, Sike He, Junru Chen, Yuntian Chen, Qiyu Zhu, Junjie Zhao, Yifu Shi, Yanfeng Tang, Xingming Zhang, Jiayu Liang, Jinge Zhao, Jiyan Liu, Ni Chen, Pengfei Shen, Jin Yao, Guangxi Sun, Zhenhua Liu, Hao Zeng

Institutions: Sichuan University, West China Hospital of Sichuan University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162485397

Cites:

Cited by:

Related to: